Cargando…

Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels

Estradiol (E2), mainly produced from Testosterone (T) in men, promotes visceral lipolysis. However, high visceral fat and hyperestrogenemia are features of obese hypogonadal (HG) men. Our study objectives are to evaluate relationships between circulating E2 and: (1) fat mass; (2) Estrogen Receptor α...

Descripción completa

Detalles Bibliográficos
Autores principales: Colleluori, Georgia, Aguirre, Lina E., Qualls, Clifford, Chen, Rui, Napoli, Nicola, Villareal, Dennis T., Armamento-Villareal, Reina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164305/
https://www.ncbi.nlm.nih.gov/pubmed/30181488
http://dx.doi.org/10.3390/nu10091226
_version_ 1783359568212918272
author Colleluori, Georgia
Aguirre, Lina E.
Qualls, Clifford
Chen, Rui
Napoli, Nicola
Villareal, Dennis T.
Armamento-Villareal, Reina
author_facet Colleluori, Georgia
Aguirre, Lina E.
Qualls, Clifford
Chen, Rui
Napoli, Nicola
Villareal, Dennis T.
Armamento-Villareal, Reina
author_sort Colleluori, Georgia
collection PubMed
description Estradiol (E2), mainly produced from Testosterone (T) in men, promotes visceral lipolysis. However, high visceral fat and hyperestrogenemia are features of obese hypogonadal (HG) men. Our study objectives are to evaluate relationships between circulating E2 and: (1) fat mass; (2) Estrogen Receptor α (ESR1) expression in subcutaneous adipose tissue; (3) changes in body fat after 6 months (M) of T therapy in HG men. Hypotheses: (1) existence of a range of circulating E2 associated with better body composition; (2) serum E2 determines tissue E2 sensitivity which affects response to T therapy. Men 40–74 years old, T < 300 (ng/dL), given T-cypionate for 6 months. Subjects were divided into 4-E2 categories: (1) <10.0; (2) 10.0–15.9; (3) 16.0–19.9; (4) ≥20.0 (pg/mL). Body composition (DXA), fat biopsies (liposuction), gene expression (qPCR), serum E2 and T (LC/MS), at baseline and 6 months. We enrolled 105 men; 90 completed the study. Group 2 had lower total and truncal fat mass (p < 0.01) but higher % lean mass (p < 0.001). ESR1 mRNA was the highest in group 1 (p = 0.01). At 6 months, group 1 had higher reduction in total (p = 0.03) and truncal (p = 0.01) fat. In conclusion, serum E2 = 10–15.9 (pg/mL) is associated with the best body composition profile in HG men; however, those with E2 < 10 (pg/mL) had the best response (greater fat loss) to T replacement possibly because of greater E2 sensitivity.
format Online
Article
Text
id pubmed-6164305
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61643052018-10-10 Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels Colleluori, Georgia Aguirre, Lina E. Qualls, Clifford Chen, Rui Napoli, Nicola Villareal, Dennis T. Armamento-Villareal, Reina Nutrients Article Estradiol (E2), mainly produced from Testosterone (T) in men, promotes visceral lipolysis. However, high visceral fat and hyperestrogenemia are features of obese hypogonadal (HG) men. Our study objectives are to evaluate relationships between circulating E2 and: (1) fat mass; (2) Estrogen Receptor α (ESR1) expression in subcutaneous adipose tissue; (3) changes in body fat after 6 months (M) of T therapy in HG men. Hypotheses: (1) existence of a range of circulating E2 associated with better body composition; (2) serum E2 determines tissue E2 sensitivity which affects response to T therapy. Men 40–74 years old, T < 300 (ng/dL), given T-cypionate for 6 months. Subjects were divided into 4-E2 categories: (1) <10.0; (2) 10.0–15.9; (3) 16.0–19.9; (4) ≥20.0 (pg/mL). Body composition (DXA), fat biopsies (liposuction), gene expression (qPCR), serum E2 and T (LC/MS), at baseline and 6 months. We enrolled 105 men; 90 completed the study. Group 2 had lower total and truncal fat mass (p < 0.01) but higher % lean mass (p < 0.001). ESR1 mRNA was the highest in group 1 (p = 0.01). At 6 months, group 1 had higher reduction in total (p = 0.03) and truncal (p = 0.01) fat. In conclusion, serum E2 = 10–15.9 (pg/mL) is associated with the best body composition profile in HG men; however, those with E2 < 10 (pg/mL) had the best response (greater fat loss) to T replacement possibly because of greater E2 sensitivity. MDPI 2018-09-04 /pmc/articles/PMC6164305/ /pubmed/30181488 http://dx.doi.org/10.3390/nu10091226 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Colleluori, Georgia
Aguirre, Lina E.
Qualls, Clifford
Chen, Rui
Napoli, Nicola
Villareal, Dennis T.
Armamento-Villareal, Reina
Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels
title Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels
title_full Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels
title_fullStr Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels
title_full_unstemmed Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels
title_short Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels
title_sort adipocytes esr1 expression, body fat and response to testosterone therapy in hypogonadal men vary according to estradiol levels
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164305/
https://www.ncbi.nlm.nih.gov/pubmed/30181488
http://dx.doi.org/10.3390/nu10091226
work_keys_str_mv AT colleluorigeorgia adipocytesesr1expressionbodyfatandresponsetotestosteronetherapyinhypogonadalmenvaryaccordingtoestradiollevels
AT aguirrelinae adipocytesesr1expressionbodyfatandresponsetotestosteronetherapyinhypogonadalmenvaryaccordingtoestradiollevels
AT quallsclifford adipocytesesr1expressionbodyfatandresponsetotestosteronetherapyinhypogonadalmenvaryaccordingtoestradiollevels
AT chenrui adipocytesesr1expressionbodyfatandresponsetotestosteronetherapyinhypogonadalmenvaryaccordingtoestradiollevels
AT napolinicola adipocytesesr1expressionbodyfatandresponsetotestosteronetherapyinhypogonadalmenvaryaccordingtoestradiollevels
AT villarealdennist adipocytesesr1expressionbodyfatandresponsetotestosteronetherapyinhypogonadalmenvaryaccordingtoestradiollevels
AT armamentovillarealreina adipocytesesr1expressionbodyfatandresponsetotestosteronetherapyinhypogonadalmenvaryaccordingtoestradiollevels